ITMI20080187A1 - Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo - Google Patents

Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo

Info

Publication number
ITMI20080187A1
ITMI20080187A1 IT000187A ITMI20080187A ITMI20080187A1 IT MI20080187 A1 ITMI20080187 A1 IT MI20080187A1 IT 000187 A IT000187 A IT 000187A IT MI20080187 A ITMI20080187 A IT MI20080187A IT MI20080187 A1 ITMI20080187 A1 IT MI20080187A1
Authority
IT
Italy
Prior art keywords
paracetamol
hepatic
prevention
damage
amino acid
Prior art date
Application number
IT000187A
Other languages
English (en)
Inventor
Pierro Francesco Di
Original Assignee
Velleja Res Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velleja Res Srl filed Critical Velleja Res Srl
Priority to IT000187A priority Critical patent/ITMI20080187A1/it
Priority to EP08802695.0A priority patent/EP2252279B1/en
Priority to PCT/EP2008/008261 priority patent/WO2009097874A1/en
Publication of ITMI20080187A1 publication Critical patent/ITMI20080187A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT000187A 2008-02-07 2008-02-07 Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo ITMI20080187A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT000187A ITMI20080187A1 (it) 2008-02-07 2008-02-07 Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
EP08802695.0A EP2252279B1 (en) 2008-02-07 2008-09-29 Amino acid formulations comprising cysteine, methionine and serine for the prevention of paracetamol-induced liver damage
PCT/EP2008/008261 WO2009097874A1 (en) 2008-02-07 2008-09-29 Amino acid formulations comprising cysteine, methionine and/or serine for the prevention of paracetamol-induced liver damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000187A ITMI20080187A1 (it) 2008-02-07 2008-02-07 Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo

Publications (1)

Publication Number Publication Date
ITMI20080187A1 true ITMI20080187A1 (it) 2009-08-08

Family

ID=40159372

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000187A ITMI20080187A1 (it) 2008-02-07 2008-02-07 Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo

Country Status (3)

Country Link
EP (1) EP2252279B1 (it)
IT (1) ITMI20080187A1 (it)
WO (1) WO2009097874A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013175479A1 (en) 2012-05-24 2013-11-28 Hadasit Medical Research Services And Development Ltd. Compositions comprising isosilybin b for amelioration and prevention of drug- induced toxicity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GB9305058D0 (en) * 1993-03-12 1993-04-28 Penn Pharm Ltd Pharmaceutical compositions
FR2744917B1 (fr) * 1996-02-16 1998-04-10 Kouchner Gerard Composition therapeutique a base d'acetaminophene
US6048540A (en) * 1997-01-29 2000-04-11 Chong Kun Dang Corp. Acetamenophen composition with reduced liver toxicity
WO2001068069A2 (en) * 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Also Published As

Publication number Publication date
EP2252279A1 (en) 2010-11-24
EP2252279B1 (en) 2013-09-11
WO2009097874A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
DK2254908T3 (da) Kosmetiske eller farmaceutiske sammensætninger omfattende metalloproteinasehæmmere
PT2637710T (pt) Formulações à base de ácido hialurónico
BRPI0920082A2 (pt) forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0820381A2 (pt) Formulações farmacêuticas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
SMT201400069B (it) Formulazione farmaceutica
BRPI0921654A2 (pt) formulação farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
BRPI1011650A2 (pt) composições sólidas compreendendo ácido 5-aminolevulínico
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
EP2296713A4 (en) DISINFECTANT FORMULATION
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI1007237A2 (pt) composição farmacêutica compreendendo aleglitazar
BRPI1013037A2 (pt) "solução farmacêutica oral de telmisartan"
DK2271321T3 (da) Farmaceutisk sammensætning 271
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
ITMI20071261A1 (it) Procedimento per la preparazione di cinacalcet
BRPI0810790A2 (pt) Formulações de aminoácidos n-halogenados
BRPI0913709A2 (pt) "formulação farmacêutica"
ITMI20080187A1 (it) Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
BRPI0811073A2 (pt) Formulações de amino ácido -n-halogenado contendo ácido alifático